Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1
1 other identifier
interventional
516
1 country
11
Brief Summary
The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jun 2003
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2003
CompletedFirst Submitted
Initial submission to the registry
February 19, 2004
CompletedFirst Posted
Study publicly available on registry
February 20, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2005
CompletedJanuary 12, 2017
April 1, 2010
1.9 years
February 19, 2004
January 11, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Opiate abstinence
Interventions
Eligibility Criteria
You may qualify if:
- Females are not pregnant or lactating
- Subjects meet DSM-IV criteria for opiate dependence, are medically and psychiatrically stable, and do not have a current history of benzodiazepine dependence abuse, dependence, or treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (11)
Addiction Research & Treatment Services (ARTS)
Denver, Colorado, 80204, United States
Denver Health & Hospitals Authority
Denver, Colorado, 80204, United States
Hartford Dispensary
Hartford, Connecticut, 06120, United States
Connecticut Counseling Centers
Waterbury, Connecticut, 06705, United States
LI Jewish Health System
Glen Oaks, New York, 11004, United States
New York VA Medical Center
New York, New York, 10010, United States
South Light-Wakeview Clinic
Raleigh, North Carolina, 27610, United States
Coastal Horizons Center, Inc.
Wilmington, North Carolina, 28412, United States
CODA
Portland, Oregon, 97214, United States
Norfolk CSB
Norfolk, Virginia, 23505, United States
Providence Behavioral Health Services
Everett, Washington, 98201, United States
Related Publications (4)
Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013 Jan-Feb;7(1):33-8. doi: 10.1097/ADM.0b013e318277e92e.
PMID: 23222095DERIVEDHillhouse M, Canamar CP, Ling W. Predictors of outcome after short-term stabilization with buprenorphine. J Subst Abuse Treat. 2013 Mar;44(3):336-42. doi: 10.1016/j.jsat.2012.08.016. Epub 2012 Sep 26.
PMID: 23021099DERIVEDBack SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23. doi: 10.3109/00952990.2011.596982.
PMID: 21854273DERIVEDLing W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009 Feb;104(2):256-65. doi: 10.1111/j.1360-0443.2008.02455.x.
PMID: 19149822DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Walter Ling, M.D.
University of California, Los Angeles
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Purpose
- TREATMENT
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 19, 2004
First Posted
February 20, 2004
Study Start
June 1, 2003
Primary Completion
May 1, 2005
Study Completion
May 1, 2005
Last Updated
January 12, 2017
Record last verified: 2010-04